- In January 2022, The US Food and Drug Administration (FDA) had approved AbbVie's SKYRIZI (risankizumab-rzaa) for the treatment of individuals with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and affects around 30% of psoriasis patients
